FindTrial
Sign In

A Phase IIb, Multicentre, Randomised, Double-Blind, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Balcinrenone in Combination with Dapagliflozin Compared with Dapagliflozin in Patients with Chronic Kidney Disease and Albuminuria

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-509709-63-00
Acronym
D6405C00002
Enrollment
85
Registered
2024-07-09
Start date
2024-07-30
Completion date
2025-05-09
Last updated
2025-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease and Albuminuria

Brief summary

Relative change in UACR from baseline to Week 12

Interventions

DRUGForxiga 10 mg film-coated tablets
DRUGBalcinrenone+Dapagliflozin
DRUGForxiga

Sponsors

AstraZeneca AB
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Relative change in UACR from baseline to Week 12—

Countries

Austria, Bulgaria, Italy, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026